Our first-in-class CRS decision support platform will provide actionable clinical insights and quantifiable biological data about the patient’s sinonasal inflammatory profile, revolutionising the way chronic nasal disorders are monitored and treated.
Nasal fluid represents a source of abundant information that can be leveraged to develop new tests and therapies for nasal disorders.
To analyse it, our technology combines state of the art materials, proteomics and machine learning to generate objective biological information.
This information can be used:
Our platform can be used for differential diagnosis, treatment monitoring and to assess disease progression.
This novel approach provides an additional layer of objective and specific biological data that is otherwise not captured during standard of care procedures such as CT imaging and nasal endoscopy.
Our technology leverages novel materials to procure precise sample volumes compared to traditional swabs or lavage techniques
Our technology analyses multiple proven “molecular fingerprints” and uses machine learning algorithms to report actionable clinical insights
Compared to traditional ENT tools, our technology is specific to the type of inflammation and provides quantitative information
Nasal sampling is safe, reliable and easily administered, particularly for needlephobic patients
Localised biomarker analysis reduces inaccuracy present in blood biomarkers due to other comorbidities and systemic factors
Proteins regulate all cell functions and change dynamically throughout the disease progression
